Theravance Biopharma TBPH Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Theravance Biopharma’s reported figures.
Based on trailing twelve months.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's return on equity?
- Theravance Biopharma (TBPH) reported return on equity of 50.2% in Q1 2026.
- How has Theravance Biopharma's return on equity changed year-over-year?
- Theravance Biopharma's return on equity increased by 259.5% year-over-year, from -31.5% to 50.2%.
- What is the long-term trend for Theravance Biopharma's return on equity?
- Over 2 years (2023 to 2025), Theravance Biopharma's return on equity has grown at a 63.1% compound annual growth rate (CAGR), from -16.9% to 44.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.